Yes, Cipla is an Indian company. Cipla is an Indian multinational pharmaceutical corporation with its headquarters at Mumbai, Maharashtra, India. Cipla provides more than 1500 prescription drugs for treating various illnesses, including asthma, cardiovascular disease as well as arthritis, diabetes chronic urological conditions and central nervous system disorders depression HIV as well as paediatric ailments. Additionally, the company makes consumer health products, such as Nicotex and ActivKids along with veterinary medicines.

Cipla’s stated aim is to facilitate access to high-quality, affordable drugs, focusing on the chronic and infectious illnesses. Cipla has 55 subsidiaries across the globe which include Cipla America Inc., Cipla Therapeutics., InvaGen Pharmaceuticals, Cipla Health Limited, Cipla Medpro South Africa Limited, and Cipla Pharma Lanka.

Company History

Cipla was established with the name of Chemical, Industrial and Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935. Through the Second World War, the company was a major source of quinine and vitamin B12 formulations for the Allied forces. In 1984, the company changed it’s name down to Cipla.

In 1995 Cipla led the way in the creation of first oral Iron Chelator for Thalassemia Treatment called Deferiprone. Cipla co-founded the Indian Pharmaceutical Alliance in the year 1999 in order to encourage creation of generic medicines in India. Cipla released a cost-effective version of an antiretroviral 3-drug medication for treating AIDS at the end of 2001. In 2005, Cipla created Tamiflu at a price that was affordable.

Cipla purchased 51 percent stakes in South Africa’s Medpro in 2013. Other notable acquisitions of its comprise InvaGen Pharmaceuticals and Exelan Pharmaceuticals in the United States during 2015-16 period. In the year 2020 Cipla obtained DCGI acceptance for their medication Covid-19, Favipiravir.

Current Status

Cipla is the third largest pharmaceutical maker in India. The company has three manufacturing plants in India along with 13 facilities for manufacturing in different countries. Cipla exports products into more than 80 countries. The majority of sales originate from India followed by the United States and South Africa. The company has over 4000 affiliates across India.

Cipla is a strong field that exceeds 7500 members, which covers around 85 percent of physicians in India. Cipla continues to invest heavily in R&D especially in the field of biosimilars and electronic health instruments.

Future Outlook

Cipla intends to expand its business in its expansion plans in the United States, with a ambition to get over 10 ANDA approvals each year, with a focus with regard to respiratory products, peptides and. Cipla is expected to invest 6-7% of its revenue for research and development in the next few time, with specific emphasis on oncology CNS treatments and biosimilars.